行情

ATNM

ATNM

Actinium制药
AMEX

实时行情|Nasdaq Last Sale

0.1800
-0.0067
-3.57%
已收盘, 19:49 04/02 EDT
开盘
0.1900
昨收
0.1867
最高
0.1900
最低
0.1800
成交量
55.67万
成交额
--
52周最高
0.6100
52周最低
0.1685
市值
2,955.08万
市盈率(TTM)
-1.0164
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ATNM价格均价为2.750,最高价位4.000,最低价为1.500。

EPS

ATNM 新闻

更多
  • Actinium Treats First Patient in AML Study on Actimab-A Combo
  • Zacks · 03/06 15:56
  • Actinium Pharma up 24% on advancement of Actimab-A in AML
  • Seeking Alpha - Article · 03/05 16:17
  • Actinium Pharma Reports First Patient Treated In Third, Final Dose Cohort Of Actimab-A CLAG-M Combo Phase 1 Trial In ACute Myeloid Leukemia
  • Benzinga · 03/05 12:40
  • Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia
  • PR Newswire · 03/05 12:30

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

ATNM 简况

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
展开

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。